Literature DB >> 21847880

Off-label drug use and promotion: balancing public health goals and commercial speech.

Aaron S Kesselheim1.   

Abstract

Mesh：

Year:  2011        PMID： 21847880     DOI： 10.1177/009885881103700202

Source DB:  PubMed          Journal:  Am J Law Med        ISSN： 0098-8588


× No keyword cloud information.
  6 in total

1.  Development and use of new therapeutics for rare diseases: views from patients, caregivers, and advocates.

Authors:  Aaron S Kesselheim; Sarah McGraw; Lauren Thompson; Kelly O'Keefe; Joshua J Gagne
Journal:  Patient       Date:  2015-02       Impact factor: 3.883

2.  Considering the Future of Pharmaceutical Promotions in Social Media Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".

Authors:  Francesca Renee Dillman Carpentier
Journal:  Int J Health Policy Manag       Date:  2016-02-09

3.  Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines.

Authors:  Kristina Klara; Jeanie Kim; Joseph S Ross
Journal:  J Gen Intern Med       Date:  2018-02-26       Impact factor: 5.128

4.  The First Amendment Right to Speak About the Human Genome.

Authors:  Barbara J Evans
Journal:  Univ Pa J Const Law       Date:  2014-02-01

5.  Ethical issues in new drug prescribing.

Authors:  Lindsay W Cole; Jennifer C Kesselheim; Aaron S Kesselheim
Journal:  J Bioeth Inq       Date:  2011-12-15       Impact factor: 1.352

6.  In vitro inhibition of platelets aggregation with generic form of clopidogrel versus branded in patients with stable angina pectoris.

Authors:  Rza Hajizadeh; Samad Ghaffari; Mojtaba Ziaee; Behrooz Shokouhi; Ahmad Separham; Parvin Sarbakhsh
Journal:  J Cardiovasc Thorac Res       Date:  2017-10-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.